These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 28584788)

  • 41. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M; Zheng C; Gao F
    Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
    Yang JS; Kim KJ; Choi H; Lee SH
    Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.
    Tiberi S; du Plessis N; Walzl G; Vjecha MJ; Rao M; Ntoumi F; Mfinanga S; Kapata N; Mwaba P; McHugh TD; Ippolito G; Migliori GB; Maeurer MJ; Zumla A
    Lancet Infect Dis; 2018 Jul; 18(7):e183-e198. PubMed ID: 29580819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Facing multi-drug resistant tuberculosis.
    Sotgiu G; Migliori GB
    Pulm Pharmacol Ther; 2015 Jun; 32():144-8. PubMed ID: 24792579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
    Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
    J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. News on therapeutic management of MDR-tuberculosis: a literature review.
    Barthod L; Lopez JG; Curti C; Bornet C; Roche M; Montana M; Vanelle P
    J Chemother; 2018 Feb; 30(1):1-15. PubMed ID: 28651480
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic.
    Tiberi S; Vjecha MJ; Zumla A; Galvin J; Migliori GB; Zumla A
    Int J Infect Dis; 2021 Dec; 113 Suppl 1():S96-S99. PubMed ID: 33713815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania.
    Mpagama SG; Mvungi HC; Mbelele PM; Semvua HH; Liyoyo AA; de Guex KP; Sloan D; Kibiki GS; Boeree M; Phillips PPJ; Heysell SK
    Pilot Feasibility Stud; 2023 Apr; 9(1):55. PubMed ID: 37005695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk Factors for Multidrug-resistant Tuberculosis.
    Rumende CM
    Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cursed duet today: Tuberculosis and HIV-coinfection.
    Tiberi S; Carvalho AC; Sulis G; Vaghela D; Rendon A; Mello FC; Rahman A; Matin N; Zumla A; Pontali E
    Presse Med; 2017 Mar; 46(2 Pt 2):e23-e39. PubMed ID: 28256380
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New anti-tuberculosis drugs and regimens: 2015 update.
    D'Ambrosio L; Centis R; Sotgiu G; Pontali E; Spanevello A; Migliori GB
    ERJ Open Res; 2015 May; 1(1):. PubMed ID: 27730131
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estimated generic prices for novel treatments for drug-resistant tuberculosis.
    Gotham D; Fortunak J; Pozniak A; Khoo S; Cooke G; Nytko FE; Hill A
    J Antimicrob Chemother; 2017 Apr; 72(4):1243-1252. PubMed ID: 28073970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
    Kakkar AK; Dahiya N
    Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs.
    Sullivan T; Ben Amor Y
    Emerg Infect Dis; 2016 Mar; 22(3):. PubMed ID: 26889711
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.
    Zhang Q; Liu Y; Tang S; Sha W; Xiao H
    Cell Biochem Biophys; 2013; 67(3):957-63. PubMed ID: 23546935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Delamanid expanded access novel treatment of drug resistant tuberculosis.
    Rustomjee R; Zumla A
    Infect Drug Resist; 2015; 8():359-66. PubMed ID: 26604805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.